Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04792073 · ClinicalTrials.gov registry record · Phase 2
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
A Phase 2 study of Merkel Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 7
- Study locations
NCT04792073 is a Phase 2 study of Merkel Cell Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 18 participants, below the 50-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (64% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT04792073, a Phase 2 study of Merkel Cell Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will test the use of comprehensive ablative radiation therapy (CART), with the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has progressed after treatment and cannot be removed with surgery. The study researchers want to find out if CART works well when combined with avelumab.
Conditions Studied
Interventions
- DRUG Avelumab
- RADIATION Comprehensive Ablative Radiation Therapy
Study Locations (7)
New York
- Memorial Sloan Kettering Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04792073
The ClinicalTrials.gov registry entry for NCT04792073 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 50-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (64% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Merkel Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Avelumab is the first listed.
NCT04792073 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04792073 about?
NCT04792073 is a clinical study titled "Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma". This study will test the use of comprehensive ablative radiation therapy (CART), with the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has progressed after treatment and cannot be removed with surgery. The study researchers want to find out if CART works well when com...
What is the current status of trial NCT04792073?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-03-08. Estimated completion is 2026-03.
What conditions does trial NCT04792073 study?
This clinical trial studies the following conditions: Merkel Cell Carcinoma.
What interventions are being tested in trial NCT04792073?
The interventions under investigation include: Avelumab (DRUG), Comprehensive Ablative Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT04792073?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04792073 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Merkel Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
RECRUITING · Phase 2
-
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.